338 related articles for article (PubMed ID: 19233866)
1. Sphingosine-1-phosphate as a mediator of high-density lipoprotein effects in cardiovascular protection.
Sattler K; Levkau B
Cardiovasc Res; 2009 May; 82(2):201-11. PubMed ID: 19233866
[TBL] [Abstract][Full Text] [Related]
2. Sphingosine-1-phosphate: A bioactive lipid that confers high-density lipoprotein with vasculoprotection mediated by nitric oxide and prostacyclin.
Rodríguez C; González-Díez M; Badimon L; Martínez-González J
Thromb Haemost; 2009 Apr; 101(4):665-73. PubMed ID: 19350109
[TBL] [Abstract][Full Text] [Related]
3. [Measurement of sphingosine 1-phosphate as a biomarker of atherosclerosis].
Kimura T; Okajima F; Murakami M
Rinsho Byori; 2007 Apr; 55(4):358-62. PubMed ID: 17511266
[TBL] [Abstract][Full Text] [Related]
4. Targeting sphingosine-1-phosphate signalling for cardioprotection.
Kennedy S; Kane KA; Pyne NJ; Pyne S
Curr Opin Pharmacol; 2009 Apr; 9(2):194-201. PubMed ID: 19070545
[TBL] [Abstract][Full Text] [Related]
5. High-density lipoproteins and their constituent, sphingosine-1-phosphate, directly protect the heart against ischemia/reperfusion injury in vivo via the S1P3 lysophospholipid receptor.
Theilmeier G; Schmidt C; Herrmann J; Keul P; Schäfers M; Herrgott I; Mersmann J; Larmann J; Hermann S; Stypmann J; Schober O; Hildebrand R; Schulz R; Heusch G; Haude M; von Wnuck Lipinski K; Herzog C; Schmitz M; Erbel R; Chun J; Levkau B
Circulation; 2006 Sep; 114(13):1403-9. PubMed ID: 16982942
[TBL] [Abstract][Full Text] [Related]
6. Assessment of the role of sphingosine 1-phosphate and its receptors in high-density lipoprotein-induced stimulation of astroglial cell function.
Malchinkhuu E; Sato K; Muraki T; Ishikawa K; Kuwabara A; Okajima F
Biochem J; 2003 Mar; 370(Pt 3):817-27. PubMed ID: 12470300
[TBL] [Abstract][Full Text] [Related]
7. High-density lipoprotein stimulates endothelial cell migration and survival through sphingosine 1-phosphate and its receptors.
Kimura T; Sato K; Malchinkhuu E; Tomura H; Tamama K; Kuwabara A; Murakami M; Okajima F
Arterioscler Thromb Vasc Biol; 2003 Jul; 23(7):1283-8. PubMed ID: 12775579
[TBL] [Abstract][Full Text] [Related]
8. HDL and its sphingosine-1-phosphate content in cardioprotection.
Keul P; Sattler K; Levkau B
Heart Fail Rev; 2007 Dec; 12(3-4):301-6. PubMed ID: 17554629
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular effects of sphingosine-1-phosphate (S1P).
Levkau B
Handb Exp Pharmacol; 2013; (216):147-70. PubMed ID: 23563656
[TBL] [Abstract][Full Text] [Related]
10. Native and reconstituted HDL activate Stat3 in ventricular cardiomyocytes via ERK1/2: role of sphingosine-1-phosphate.
Frias MA; James RW; Gerber-Wicht C; Lang U
Cardiovasc Res; 2009 May; 82(2):313-23. PubMed ID: 19151362
[TBL] [Abstract][Full Text] [Related]
11. HDL-like lipoproteins in cerebrospinal fluid affect neural cell activity through lipoprotein-associated sphingosine 1-phosphate.
Sato K; Malchinkhuu E; Horiuchi Y; Mogi C; Tomura H; Tosaka M; Yoshimoto Y; Kuwabara A; Okajima F
Biochem Biophys Res Commun; 2007 Aug; 359(3):649-54. PubMed ID: 17544365
[TBL] [Abstract][Full Text] [Related]
12. HDL serves as a S1P signaling platform mediating a multitude of cardiovascular effects.
Argraves KM; Argraves WS
J Lipid Res; 2007 Nov; 48(11):2325-33. PubMed ID: 17698855
[TBL] [Abstract][Full Text] [Related]
13. Sphingosine 1-phosphate levels in plasma and HDL are altered in coronary artery disease.
Sattler KJ; Elbasan S; Keul P; Elter-Schulz M; Bode C; Gräler MH; Bröcker-Preuss M; Budde T; Erbel R; Heusch G; Levkau B
Basic Res Cardiol; 2010 Nov; 105(6):821-32. PubMed ID: 20652276
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of cardioprotection by lysophospholipids.
Karliner JS
J Cell Biochem; 2004 Aug; 92(6):1095-103. PubMed ID: 15258895
[TBL] [Abstract][Full Text] [Related]
15. Erythrocytes serve as a reservoir for cellular and extracellular sphingosine 1-phosphate.
Bode C; Sensken SC; Peest U; Beutel G; Thol F; Levkau B; Li Z; Bittman R; Huang T; Tölle M; van der Giet M; Gräler MH
J Cell Biochem; 2010 Apr; 109(6):1232-43. PubMed ID: 20186882
[TBL] [Abstract][Full Text] [Related]
16. Defects of High-Density Lipoproteins in Coronary Artery Disease Caused by Low Sphingosine-1-Phosphate Content: Correction by Sphingosine-1-Phosphate-Loading.
Sattler K; Gräler M; Keul P; Weske S; Reimann CM; Jindrová H; Kleinbongard P; Sabbadini R; Bröcker-Preuss M; Erbel R; Heusch G; Levkau B
J Am Coll Cardiol; 2015 Sep; 66(13):1470-85. PubMed ID: 26403344
[TBL] [Abstract][Full Text] [Related]
17. Tipping the gatekeeper: S1P regulation of endothelial barrier function.
Rosen H; Sanna MG; Cahalan SM; Gonzalez-Cabrera PJ
Trends Immunol; 2007 Mar; 28(3):102-7. PubMed ID: 17276731
[TBL] [Abstract][Full Text] [Related]
18. Atheroprotective role of high-density lipoprotein (HDL)-associated sphingosine-1-phosphate (S1P).
Potì F; Simoni M; Nofer JR
Cardiovasc Res; 2014 Aug; 103(3):395-404. PubMed ID: 24891400
[TBL] [Abstract][Full Text] [Related]
19. Activation of sphingosine-1-phosphate signalling as a potential underlying mechanism of the pleiotropic effects of statin therapy.
Egom EE; Rose RA; Neyses L; Soran H; Cleland JG; Mamas MA
Crit Rev Clin Lab Sci; 2013; 50(3):79-89. PubMed ID: 23885725
[TBL] [Abstract][Full Text] [Related]
20. High-density lipoprotein from end-stage renal disease patients exhibits superior cardioprotection and increase in sphingosine-1-phosphate.
Brinck JW; Thomas A; Brulhart-Meynet MC; Lauer E; Frej C; Dahlbäck B; Stenvinkel P; James RW; Frias MA
Eur J Clin Invest; 2018 Feb; 48(2):. PubMed ID: 29178180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
